News | Treatment Planning | October 18, 2019

MD Anderson and Varian Partner to Optimize Radiation Oncology Treatment

Partnership will connect participating sites to a central database to streamline review of radiation therapy treatment plans

MD Anderson and Varian Partner to Optimize Radiation Oncology Treatment

October 18, 2019 — The University of Texas MD Anderson Cancer Center and Varian announced a new strategic collaboration to develop an integrated software platform to streamline review of radiation oncology treatment plans.

The goal of the platform is to establish an efficient framework to connect participating sites to a central database, allowing MD Anderson physicians to host collaborative review sessions around treatment plans and to communicate plan changes back to physicians. As the platform matures, it has the potential to be deployed at all MD Anderson locations and across MD Anderson Cancer Network.

“Radiation oncology is a highly technical specialty that relies on the interoperability of a variety of hardware and software components,” said Albert Koong, M.D., Ph.D., professor and division head of radiation oncology at MD Anderson. “We believe the development of this unified platform with Varian will enable expansion of our radiation oncology quality standards to provide the best available care to more patients.”

Watch the VIDEO: Walk Around of a Varian Identify Image-guided Patient Positioning System

MD Anderson Cancer Network, a program of MD Anderson Cancer Center, collaborates with community hospitals and healthcare systems around the globe to provide higher quality and advanced care to patients in the communities in which they live.

In addition to the software platform, the partnership will work to develop evidence-based tools to improve the analysis of various quality measures, with a focus on:

  • Minimizing the volume of radiation dose distributed to nearby healthy organs, resulting in fewer side effects for patients;
  • Automating the comparison of treatment plans to MD Anderson and national quality criteria, enabling the development of new standard value and safety metrics; and
  • Decreasing the time needed to review radiation treatment plans, improving efficiency and expanding access.

For more information: www.varian.com, www.mdanderson.org

Related Content

Researchers at Karolinska Institutet in Sweden and Tampere University in Finland have developed a method based on artificial intelligence (AI) for histopathological diagnosis and grading of prostate cancer

From left: Peter Ström, Martin Eklund, Kimmo Kartasalo, Henrik Olsson och Lars Egevad, researchers at Karolinska Institutet in Sweden. Photo courtesy of Stefan Zimmerman

News | Prostate Cancer | January 20, 2020
January 20, 2020 — Researchers at Karolinska Institutet in Sweden and...
Trends in Overall Cancer Mortality Rates by Sex, United States, 1930 to 2017. Rates are age adjusted to the 2000 US standard population

Trends in Overall Cancer Mortality Rates by Sex, United States, 1930 to 2017. Rates are age adjusted to the 2000 US standard population. Chart courtesy of the American Cancer Society

News | Radiation Oncology | January 13, 2020
January 13, 2020 — The cancer death rate declined
Professor Samer Ezziddin, M.D., from Saarland University/Saarland University Hospital.

Professor Samer Ezziddin, M.D., from Saarland University/Saarland University Hospital. Image courtesy of Saarland University/Thorsten Mohr

 

News | Prostate Cancer | January 13, 2020
January 13, 2020 — When a non-scientist tries to imagine a scientist, the image that often arises is one of a somewha
Lung cancer patients who are inactive prior to chemoradiation are less likely to tolerate treatment and more likely to see their cancer return
News | Lung Cancer | January 08, 2020
January 8, 2020 — Numerous ...
Six of the top 20 radiotherapy stories in 2019 involved proton therapy. This includes two video inetrviews shot during a site visit to the Northwestern Medicine Proton Center in the Chicago suburb of Warrenville, Ill.

Six of the top 20 radiotherapy stories in 2019 involved proton therapy. This includes two video inetrviews shot during a site visit to the Northwestern Medicine Proton Center in the Chicago suburb of Warrenville, Ill.

Feature | Radiation Oncology | January 03, 2020 | Dave Fornell, Editor
January 3, 2020 — Here is the top 20 pieces of radiation oncology content on the Imaging Technology News (ITN) websit
Artificial intelligence was by far the hottest topic in both radiology and radiation oncology in 2019, and AI is the subject of 8 of the top 2019 ITN videos. This image is a prostate treatment plan created autonomously by an AI algorithm from RaySearch and is the subject of the No. 2 video on the list. Deep learning in radiology and radiation oncology.

Artificial intelligence was by far the hottest topic in both radiology and radiation oncology in 2019, and AI is the subject of 8 of the top 2019 ITN videos. This image is a prostate treatment plan created autonomously by a machine learning algorithm from RaySearch and is the subject of the No. 2 video on the list. 

Feature | December 30, 2019
Here are the top 20 best performing videos posted on the Imaging Technology News website (ITN) from the past year, ba
Ferrotran (formerly Combidex), based on Ferumoxtran-10, is the only contrast agent which can detect lymph node metastases as small as 2 mm diameter

Ferrotran (formerly Combidex), based on Ferumoxtran-10, is the only contrast agent which can detect lymph node metastases as small as 2 mm diameter. Standard MRI or CT are not able to detect lymph node metastases smaller than 7 – 8 mm. Since most of the oncologic patients are dying due to metastases, a precise diagnostic is of utmost importance. The detection of small metastases, combined with the very clear and contrast rich MRI image of Ferrotran, enables an earlier and more precise treatment. Therefore, Ferrotran gives the patient a much higher chance of recovery.

News | Prostate Cancer | December 24, 2019
December 24, 2019 — SPL Medical announced today that the first patient has been successfully diagnosed with suspected